E-viri
Odprti dostop
-
Salmon, Jessica M; Todorovski, Izabela; Stanley, Kym L; Bruedigam, Claudia; Kearney, Conor J; Martelotto, Luciano G; Rossello, Fernando; Semple, Timothy; Arnau, Gisela Mir; Zethoven, Magnus; Bots, Michael; Bjelosevic, Stefan; Cluse, Leonie A; Fraser, Peter J; Litalien, Veronique; Vidacs, Eva; McArthur, Kate; Matthews, Antony Y; Gressier, Elise; de Weerd, Nicole A; Lichte, Jens; Kelly, Madison J; Hogg, Simon J; Hertzog, Paul J; Kats, Lev M; Vervoort, Stephin J; De Carvalho, Daniel D; Scheu, Stefanie; Bedoui, Sammy; Kile, Benjamin T; Lane, Steven W; Perkins, Andrew C; Wei, Andrew H; Dominguez, Pilar M; Johnstone, Ricky W
Cancer discovery, 06/2022, Letnik: 12, Številka: 6Journal Article
Pharmacologic inhibition of epigenetic enzymes can have therapeutic benefit against hematologic malignancies. In addition to affecting tumor cell growth and proliferation, these epigenetic agents may induce antitumor immunity. Here, we discovered a novel immunoregulatory mechanism through inhibition of histone deacetylases (HDAC). In models of acute myeloid leukemia (AML), leukemia cell differentiation and therapeutic benefit mediated by the HDAC inhibitor (HDACi) panobinostat required activation of the type I interferon (IFN) pathway. Plasmacytoid dendritic cells (pDC) produced type I IFN after panobinostat treatment, through transcriptional activation of IFN genes concomitant with increased H3K27 acetylation at these loci. Depletion of pDCs abrogated panobinostat-mediated induction of type I IFN signaling in leukemia cells and impaired therapeutic efficacy, whereas combined treatment with panobinostat and IFNα improved outcomes in preclinical models. These discoveries offer a new therapeutic approach for AML and demonstrate that epigenetic rewiring of pDCs enhances antitumor immunity, opening the possibility of exploiting this approach for immunotherapies. We demonstrate that HDACis induce terminal differentiation of AML through epigenetic remodeling of pDCs, resulting in production of type I IFN that is important for the therapeutic effects of HDACis. The study demonstrates the important functional interplay between the immune system and leukemias in response to HDAC inhibition. This article is highlighted in the In This Issue feature, p. 1397.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.